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Summary Active vitamin. D3 modulates epidermal growth, keratinization and inflammation, and various vitamin
D3 analogues have been shown to be effective in the treatment of psoriasis. These analogues now 
provide a useful addition to the therapeutic modalities available for the treatment of psoriasis. Epidermal 
hyperproliferation, abnormal keratinization and inflammation are the well-established hallmarks of the 
psoriatic plaque. The aim of this review is to provide an update of information on the cell biological 
effects of vitamin D3, and the influence of vitamin D analogues on the pathomechanisms of psoriasis.
Vitamin D3 is absorbed from the gut, and is also 
synthesized in the skin from 7 -dehydrocholesterol 
following exposure to ultraviolet light (290-300 nm).
It is activated by hydroxylation. 1 - 4 The classic target
organs of vitamin D3 are the gut, bones and kidneys.
Several vitamin D3 analogues have been shown to be 
effective in the management of psoriasis.
General cell biological effects
Vitamin D3 can be 'activated' by hydroxylation at the 
la  and 25 positions. Various vitamin D3 derivatives 
modulate the biological functions of many cell types. 
Two basic mechanisms are responsible for the action of 
these hormones: a nuclear mechanism involving mod­
ification of gene transcription, and a non-nuclear 
mechanism involving signalling.
Nuclear mechanisms
Active vitamin D3 binds to a nuclear receptor, the 
vitamin D3 receptor (VDR). This receptor is a ligand- 
inducible transcriptional regulatory protein, 
complex of VDR and active vitamin D3 modulates 
the transcription of target genes by binding to specific 
DNA binding sites designated ‘vitamin D response 
elements’. Vitamin D response elements are present 
in the promoter region of target genes of la , 2  5 - 
dihydroxyvitamin D3 [lo:,25-(OH)2D3].
The vitamin D receptor has been cloned and 
sequenced. This receptor demonstrates structural 
homology with known steroid receptors: glucocorticoid
receptor, oestrogen receptor, thyroid receptor and reti- 
noic acid receptors. These receptors belong to the 
nuclear receptor superfamily. The receptor has a 
domain which binds to the steroid, another which 
interacts with other members of the nuclear receptor 
superfamily, and a DNA binding domain. The vitamin D 
receptor is a high-affinity receptor for 1q;,25--(OH)2D3, 
and many cell types possess this high-affinity receptor.
The DNA binding domain of the nuclear
superfamily is characterized by two zinc 
motifs. 6 The DNA response elements to which these 
receptors bind are similar in sequence and organization.
Evidence is accumulating that the vitamin D 3 
is communicating vitamin D3-mediated signals in con­
certed action with the other members of the nuclear 
receptor superfamily. For this interaction 
members of the steroid receptor superfamily, a novel 
structural domain has been identified. This is conserved 
within the members of the nuclear receptor super family, 
and consists of a helix-turn-zipper which may function 
in transactivation of cognate genes. 7 Interaction with
retinoid-X receptor-alpha (RXR-rv) 
reported by several authors, RXR-a Interacts directly 
with, and enhances the binding of, nuclear receptors 
conferring responsiveness to vitamin 1){ and thyroid 
hormone. 8 RXR-a is a dimerization partner for the 
vitamin D3 receptor. It has been postulated that RXR- 
a enhances tight binding of VDR vitamin D
response elements. Via this principle, cross-talks are 
possible between the ligands of the steroid receptor 
superfamily. 10 The expression of the
vitamin D receptor is susceptible lo various
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mechanisms. It has been demonstrated in mouse fibro­
blasts that the vitamin D3 receptor is upregulated by
calcipotriol and la:,25(OH)2D3.11,12 The expression of
the vitamin D receptor has been shown to be 4-5-fold 
increased in rapidly proliferating endothelial cells, com­
pared with density arrested cells, which suggests that 
the expression of the receptor can be modulated by 
factors involved in growth control. 13 The vitamin D 
receptor has been shown to be upregulated by protein 
kinase C activation, and this phenomenon was pre- 
vented by sphingosine.
Various DNA response elements are available for the 
members of the nuclear receptor superfamily. The 
vitamin D3 response elements differ considerably in 
their homology to each other. 14 Vitamin D3 response 
elements are characterized by a tandem repeating 
oligonucleotide sequence of six base pairs (bp). Select­
ivity for vitamin D3 within the nuclear receptor super­
family is determined by half-site spacing of the response 
elements. Decreasing the half-site spacing of the 
response element for thyroid hormone will convert it 
to a vitamin D3 response element, whereas increasing 
the half-site spacing will convert it into a retinoic acid 
response element. 15 Recently, two classes of vitamin D 
response elements have been identified which are 
activated by the vitamin D receptor alone or by hetero­
dimers of the vitamin D receptor and RXR-a. 16
Transmembrane signalling
Active vitamin D3 has been shown to induce an 
increased influx of calcium into the cell via a non-
nuclear mechanism.17-18 The rise of the calcium
concentration within the keratinocytes has been shown 
to occur at physiological concentrations of la,25~ 
(OH)2D3 (10-11-10~9 m) . 17 The accumulation of cal­
cium in the keratinocyte occurs within 90s of the 
addition of lo:,25-(OH)2D3 to the culture medium. 17 
This timing is not compatible with a nuclear mechan­
ism. The effect of la,25-(OH)2D3 on calcium metabo­
lism is not inhibited by cycloheximide, which indicates 
that protein synthesis is not involved. In keratinocyte 
cultures, la,25-(OH)2D3 has been shown to enhance 
rapid hydrolysis of phosphatidyl inositol phosphate, 
which results in an increase of the intracellular 
concentration of calcium.
Intracellular signalling
The nuclear effects of active vitamin D3, and the more 
immediate induction of a transmembrane calcium 
influx, result in a modulation of intracellular signalling.
It has been shown that la,25~(OH)2D3 enhances 
the production of inositol trisphosphate and 1 ,2 - 
diacylglycerol, and induces an increase of intracellular 
calcium. Vitamin D3 promotes the translocation of 
protein kinase C from the cytosolic to the membrane 
position. 21 It is difficult to define to what extent the 
nuclear mechanisms or the transmembrane signalling 
are responsible for these effects.
The physiological relevance of protein kinase C as an 
intermediary stage between vitamin D3 action and 
epidermal differentiation is evident from the observa­
tion that inhibition of protein kinase C causes marked 
suppression of la-25-(OH)2D3-induced formation of
r y  j
cornified envelopes.
An increase of the intracellular calcium concentra­
tion has various biochemical effects. Increasing the 
extracellular calcium concentration in keratinocyte 
cultures results in keratinization. An increase of the 
intracellular calcium concentration occurs during 
differentiation of these cells. 22
Many cell types respond to vitamin D3. In this review, 
the cell types involved in the pathogenesis of psoriasis 
are highlighted. 11
Interference with keratinocytes
Active vitamin D3 inhibits proliferation of keratinocytes 
in culture. Incorporation of 3H-thymidine in DNA is 
inhibited by 1q!,25-(OH)2D3 at concentrations equal to
or higher than 1 0 — 10 23-29M, 1o:,25-(OH)2D3 has also
been reported to inhibit growth of malignant cell lines. 
A 3-day incubation of NIH: OVCAR 3 cells with 
100 nmol la,25-(OH)2D3 resulted in 49% inhibition 
of cell growth. 30 An antitumour effect has also been 
shown in breast carcinoma cells, and squamous carci­
noma andI-IL-60 cell lines. 31 The l-hydroxymethyI-25- 
hydroxyvitamin D3 homologues proved to have anti­
proliferative activity on murine keratinocytes similar to 
that of la ,25-dihydroxyvitamin D3.32
homologues were less than 0 -1 % as effective as vitamin 
D3 in binding to the vitamin D3 receptor.
Based on these in vitro observations, it can be concluded
vitamin 3 is
3not a direct reflection of affinity for the vitamin D 
receptor. The bioavailability of the vitamin D3 analogue 
is one explanation for this discrepancy. Some analogues 
may have different clearance rates in vivo. An alternative 
explanation is that some analogues act more specifically 
on the plasma membrane than on the nuclear pathway.
Epidermal differentiation is enhanced by active 
vitamin D3 in keratinocyte culture. Cornified envelope
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formation and transcription of transglutaminase are 
enhanced by la:-25-(OH)2D3 at concentrations of
Cl '1 ?  T O
10" m or higher. Human keratinocytes grown 
on de-epidermized dermis are able to reconstruct a 
morphologically normal stratified and keratinizing 
epidermis. It has also been shown that the stratum 
corneum is thicker under the influence of la ,2 5- 
(OH)2D3. A prominent reduction of the intermediate 
differentiation compartment was observed, 33 and it was 
shown that this reduction is not due to a block of the 
proliferation of basal cells. In air-liquid interface 
culture, 1c*,25-(OH)2D3 was shown to increase the 
number of stratum corneum layers, and to reduce 
the water permeation. 34 The interference with keratin- 
ization is different from the effect of retinoic acid. 
In contrast with the suppression of the transcription 
of keratins 3, 5, 10, 14 and 16 by retinoic acid, la ,25- 
(OH)2D3 does not induce such a suppression, la , 
25-(OH)2D3 induced transglutaminase activity in 
transformed epidermal cells (PAM 212), and this effect 
was shown to be synergistic with the induction of 
transglutaminase by retinoic acid. la,25-(OH)2D3 and 
retinoic acid induce transglutaminase via separate 
mechanisms. 35
lo!,25-(OH)2D3 increases entry of calcium into the 
keratinocyte at concentrations between 1 0 “ 11 and 
10-9 m. 17 Such a concentration is sufficient for the 
induction of modulation of keratinization. Indeed, 
increases of intracellular calcium are associated with 
keratinization.22 In this respect, it is of relevance that 
transglutaminase is calcium-dependent. 35 Via the
nuclear pathway, la,25-(OH)2D3 enhances the produc­
tion of inositol trisphosphate and 1 ,2 -diacylglycerol,21
and also enhances the transcription of protein kinase
/
C. Activation of protein kinase C is associated with 
enhanced keratinization. The molecular interphase 
between la,25-(OH)2D3 activation and the anti­
proliferative action remains to be elucidated. A dissocia­
tion between antiproliferative action and affinity for the 
vitamin D3 receptor exists for various new vitamin I) 3 
analogues. 32
Recently, it has been demonstrated in HL-60 cells 
that pretreatment with la,25-(OH)2D3 renders these 
cells more resistant to apoptosis. 37 Calcium influx into 
the cell plays an important role in events culminating in 
apoptosis, and a high level of expression of proteins 
which buffer fluxes of calcium can effectively block 
death in apoptosis-susceptible cells. 38 Although still 
highly speculative, it is attractive to postulate that 
calcium entry into cells, as induced by vitamin D3, 
might be a crucial factor in the induction of apoptosis.
As the process of keratinization might be regarded as 
apoptosis, further studies on the effect of vitamin D3 on 
the modulation of apoptosis in keratinocytes are 
indicated.
Modulation of inflammation
Active vitamin D3 interferes with various aspects of
inflammation, 
mechanisms are involved.
nuclear and non-
la,25- inhibits interleukin-1-induced T-
proliferation and the production of immunoglobulins 
by these cells. The production of interleukin 2 and
6 by T cells is by 1 a,
3 9“" 4:0 Both 1ck,25~(0H)2D3 and cyclosporin
inhibit interleukin 2 production by CD4 
compounds have been shown to
« I " »
a
effect, which implies that immunomodulation by cyclo­
sporin is different from immunomodulation by la , 
25-(OH)2D3.41,42 At the molecular level it has been 
shown that la,25-(QH)2D3 inhibits accumulation of 
mRNA for interleukin 2, interferon gamma (IFN-7 ), and 
granulocyte-macrophage colony-stimulating factor. At 
a cellular level, suppressor cell activity is promoted, and 
the generation of cytotoxic and natural killer cells is 
inhibited.43 In mice, it has been shown that topical 
application of la,25-(OH)2D3 increases contact hyper­
sensitivity at the elicitation site.44
la,25-(OH)2D3 increases cytotoxicity of macro-
45 Interferon alpha (IFN-a) and la,25-(OH)2I)
have a effect on the
monocytes-macrophages (U 937
3 
of
IFN-a
increases the expression of the vitamin I) 3 receptor in 
U 937 cells.46 la,25-(OH)2D3 down-regulates HLA-DR 
expression on human peripheral blood monocytes 
1 01,2 5-
47
promotes increas 
but decreased expression of CD23. Retinoic aci
ï8 IFN-7 é
notypic characteristics of vitamin Dr  
toid differentiation in the
monocy-
line. 49 lev, 25-(OH) 2 D3 down-regul 
receptor expression and up-regulates
50
In myeloid cells, calcium-binding proteins (MRP« and 
MRP14) are synthesized under specific conditions of
myeloid cell differentiation. lc*,25~(OH)2D3 
the expression of the genes encoding for these 
binding proteins. 51 Platelet-activating factor is a
lipid mediator of inflammation. In HL-60 cells, 
activating factor receptor gene
by la,25-(OH)2D:j. la ,25-
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strated to inhibit proliferation and enhance differentia­
tion in the HL-60 line. 31 ,53-55
In keratinocytes, interferon gamma induces the 
expression of the HLA-DR antigen, and lo:,25-
Derivatives with a preferential interference
(OH)2D3 significantly decreases 
HLA-DR expression. 56
the IFN-7 -induced
The release of arachidonic acid by polymorpho-
nuclear leucocytes is inhibited by la:)25-(OH)2D3,
C
which also inhibits migration of these cells.
57
Vitamin D3 analogues
Calcipotriol
Calcipotriol and la,25-(OH)2D3 are comparable with 
respect to receptor binding, inhibition of epidermal 
proliferation, and modulation of keratinization and 
inflammation. However, there is a striking difference 
between calcipotriol and 1û!,25-(OH)2D3 with regard to 
interference with systemic calcium metabolism. Com­
pared with la:t25-(0H)2D3, calcipotriol is rapidly meta­
bolized into inactive compounds. From animal 
experiments it has been concluded that calcipotriol is 
1 0 0 - 2 0 0  times less active than la,25-(pH)2D3 with
rü
regard to induction of hypercalcaemia.
1 a,24-dihydroxy vitamin Z) 3 (tacalcitol)
j
*
la ,2 4-dihydroxy vitamin D3 [let, 24-(0H)2D3] has an 
increased receptor affinity compared with la,25- 
(OH^Dj. 59 The inhibition of proliferation of keratino­
cytes by lct,24-(OH)2D3 has been reported to be slightly 
greater than la,25-(OH)2D3, whereas the enhance­
ment of cornified envelope formation proved to be 
comparable. 60 Although Xck,24-(0H)2D3 has been 
reported to have no effect on the polymorphonuclear 
leucocyte,60 1ck,24-(0H)2D3 and la,25-(OH)2D3 proved 
to be equipotent with respect to the inhibition of the 
antibody response to the T-cell-dependent antigen. 61 
la:,24-(OH)2D3 proved to have less effect on systemic 
calcium metabolism than la,25-(OH)2D3.62
1 (S), 3(R)-dihydroxy-20(R)-(41 -hydroxy-41 -ethyl- 
l 1-hexyloxy-9, 10-secopregna 5 (Z), 10(lg)-triene 
(KH 1060)
This derivative has a pronounced immunosuppressive
effect. In mice, KH 1060 suppressed skin-graft 
rejection, 62 and also proved to be a potent immuno-
in HgCl2-induced autoimmune
1
suppressive 
nephritis in rats.
Recently, new analogues have become available 
with a predilection for either non-nuclear or nuclear 
mechanisms. 64-66
Some analogues bind poorly to the vitamin D receptor 
but strongly stimulate the influx of calcium into the 
cell.67 Pertussis toxin, which interferes with coupling of 
certain ligand-gated receptors to ion channels, failed 
to block activation of calcium channels by vitamin D3. 
Selectivity, with only limited binding to the vitamin 
D3 receptor, has been demonstrated for the following 
analogues: 25-hydroxy-16 ene-23-yne D3 and 25- 
hydroxy-2 3 yne D3.
1 , 2  5-dihydroxy-16 ene-23 yne-vitamin D3 is four 
times more effective than l,25-(OH)2D3 with regard to 
inhibition of clonal proliferation of HL-60, EM-2, and U 
937 myeloid cell lines, and induction of differentiation 
of HL-60 promyelocytes. This analogue has been shown 
to decrease the expression of the c-myc oncogene by 
50% within 10 h. The analogue is 60% as effective in 
binding to the receptor of HL-60 cells, and is markedly 
less calcipotropic. 55 This analogue markedly prolongs 
the survival of leukaemic mice, l-hydroxymethyl-25- 
hydroxy vitamin D3 analogues have an antiproliferative 
effect comparable with la,25-(OH)2D3. However, these 
analogues have less than 0-1% affinity for the vitamin D 
receptor than la,25-(OH)2D3.30 22-oxa-l,25-(OH)2D3 
has a decreased vitamin-D-receptor affinity compared 
with la,25-(OH)2D3.68 This derivative has a more 
marked antiproliferative and differentiation enhancing 
potential than la,25-(OH)2D3.29 The 22-oxa derivative 
has been shown to have a potent immunosuppressive 
effect. 6 7
Some analogues bind well to the vitamin D receptor, 
but display little or no activity in opening the trans­
membrane calcium channels. 67 Such selectivity is a 
characteristic of the analogues l,24-dihydroxy-22- 
ene-24 cyclopropyl D3 and 1,25-16 ene-23 yne,26, 
2 7 F6 -D3 . The latter compound has been shown to 
have an 80-fold increased inhibition of HL-60 cells 
compared with 1û!,25-(0H)2D3.31 In HL-60 cell lines, 
it has been shown that the differentiation induced by 
the 26, 27-dialkyl analogues correlates well with 
receptor binding. 53
It has been shown that specific side-chain modifica­
tions affect the differentiation-inducing capacity with­
out affecting anti-proliferative potency. 66 Therefore, it 
may be possible to dissociate the antiproliferative activ­
ity from the differentiation-inducing activity by modifi­
cation of the 1ú¡,25-(0H)2D3 molecule.
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In vivo effects
Epidermal proliferation, abnormal keratinization, and 
cutaneous inflammation are key features of the psoriatic 
lesion. Vitamin D3 analogues have been shown to 
modulate these processes in vitro. However, the extent 
to which this is relevant to the antipsoriatic efficacy 
remains to be elucidated. Several studies have been 
carried out to assess changes of epidermal growth, 
differentiation and inflammation during treatment of 
psoriatic plaques with vitamin D3 analogues.
During treatment of psoriatic plaques with calcipo­
triol ointment (50 /¿g/g), it was shown that the accu­
mulation of polymorphonuclear leucocytes decreases 
during the first week of treatment; the number of 
cycling epidermal cells showed a reduction after 2  
weeks' treatment; after 4 weeks’ treatment the 
number of keratin-16-positive cells and the number of 
T lymphocytes decreased significantly. The number of 
CD 14 cells and Langerhans cells remained unaffected 
during treatment with calcipotriol. 69 A quantification 
of these changes by flow cytometry revealed a highly 
significant reduction of the percentage of cells in SG2M 
phase, and a highly significant reduction of the number 
of keratin-16-positive cells. However, even in those 
patients who showed complete clinical resolution of 
the psoriatic plaques, the percentages of keratin-16- 
positive cells and cells in SG2M phase remained well 
above the normal range. 70 During treatment of psor­
iatic plaques with calcipotriol, a reduction of the 
number of keratin-16- and keratin-17-positive cells, 
and a normalization of the number of keratin-5- and 
keratin-10-positive cells has been shown. 71-73 How­
ever, calcipotriol treatment of psoriatic plaques did not 
result in a modification of ornithine decarboxylase 
activity. 74 During treatment with calcipotriol a reduc­
tion of helper T cells and a preponderance of suppressor 
T cells was induced. 75 Most studies agree that calcipo­
triol induces pronounced changes in epidermal beha­
viour, leaving the mononuclear 
unaffected. 70 ,75 ,76 However, one study suggested a 
relative persistence of the epidermal phenomena. 74 
Compared with the effects of betamethasone valerate, 
calcipotriol induced a reduction of epidermal growth and 
differentiation characteristics to the same extent. 70 
During treatment of psoriatic plaques with calcipo­
triol, a decline of staining intensity of interleukin 6 , 
but not of tumour necrosis factor-a was observed in 
lesional and clinically uninvolved skin. 77
Studies have been carried out during treatment with 
la,25-(OH)2D3 ointment (3/ig/g) and la,24-(OH)2D3
ointment (4 fig/g). Changes similar to those seen during 
calcipotriol application were observed during these 
treatments. 78-81 Remarkably, during treatment with 
la:,25-(OH)2D3 and la,24-(OH)2D3, a reduction of the 
accumulation of T lymphocytes and monocytes was 
seen, in contrast with the inconspicuous changes 
induced by calcipotriol. 79 ,80 Systemic treatment of 
psoriatic patients with la-hydroxy vitamin D3 resulted 
in inhibition of keratinocyte proliferation and a reduc­
tion of keratin 16 expression.82
It can be concluded that a reduction of epidermal 
proliferation and a decrease in the accumulation of 
polymorphonuclear leucocytes are the most prominent 
changes during treatment of psoriatic plaques with 
vitamin D3 analogues.
Conclusions and future prospects
Vitamin D3 analogues interfere, via nuclear and non­
nuclear mechanisms, with epidermal proliferation, 
differentiation and cutaneous inflammation. Calcipo­
triol, la,25-(OH)2D3 and la,24-(OH)2D3 have been 
shown to be effective in the treatment of psoriasis. 
In vitro studies have revealed that the biological effects 
of vitamin D3 analogues are substantial and diverse. 
In vivo studies on the mode of action of vitamin D3 
during treatment of psoriatic plaques have revealed that 
an influence on epidermal proliferation and accumula­
tion of polymorphonuclear leucocytes is an early effect, 
whereas the modulation of the number of T 
monocytes and macrophages are late effects. Following 
clinical clearance of psoriatic plaques by vitamin I> 3 
analogues (calcipotriol, l«,25~(OH)2D3 and U*,24- 
(OH)2D3) the cell biological markers are reduced, but 
are still abnormal. A limitation of treatment with 
calipotriol is irritation of the skin in 2 0 % of patients.
The future of vitamin D3 analogues is bright. New 
analogues are available which have selective 
with regard to nuclear and non-nuclear mechanisms of 
iction. Separation of antiproliferative and ra 
potential has been achieved in vitro and in <
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